China Resources Pharmaceutical Group Inkomsten in het verleden
Verleden criteriumcontroles 5/6
China Resources Pharmaceutical Group has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 8% per year. China Resources Pharmaceutical Group's return on equity is 8.5%, and it has net margins of 1.5%.
Belangrijke informatie
4.3%
Groei van de winst
4.4%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 5.6% |
Inkomstengroei | 8.0% |
Rendement op eigen vermogen | 8.5% |
Nettomarge | 1.5% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Opbrengsten en kosten
Hoe China Resources Pharmaceutical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 250,483 | 3,777 | 25,588 | 0 |
31 Mar 24 | 247,593 | 3,816 | 25,420 | 0 |
31 Dec 23 | 244,704 | 3,854 | 25,252 | 0 |
30 Sep 23 | 232,564 | 3,573 | 23,906 | 0 |
30 Jun 23 | 224,656 | 3,382 | 22,961 | 0 |
31 Mar 23 | 224,587 | 3,518 | 22,783 | 0 |
31 Dec 22 | 218,183 | 3,500 | 21,999 | 0 |
30 Sep 22 | 221,487 | 3,724 | 22,247 | 0 |
30 Jun 22 | 211,788 | 3,719 | 21,193 | 0 |
31 Mar 22 | 196,226 | 3,288 | 19,674 | 0 |
31 Dec 21 | 193,021 | 3,072 | 19,393 | 0 |
30 Sep 21 | 191,495 | 2,869 | 19,667 | 0 |
30 Jun 21 | 187,554 | 2,626 | 19,701 | 0 |
31 Mar 21 | 179,512 | 2,720 | 19,092 | 0 |
31 Dec 20 | 168,762 | 2,776 | 18,197 | 0 |
30 Sep 20 | 171,873 | 2,683 | 19,137 | 0 |
30 Jun 20 | 174,956 | 2,578 | 20,122 | 0 |
31 Mar 20 | 181,054 | 2,793 | 21,233 | 0 |
31 Dec 19 | 182,690 | 2,937 | 21,813 | 0 |
30 Sep 19 | 183,417 | 3,670 | 21,984 | 0 |
30 Jun 19 | 173,938 | 4,187 | 20,930 | 0 |
31 Mar 19 | 165,679 | 3,737 | 20,069 | 0 |
31 Dec 18 | 166,626 | 3,494 | 20,322 | 0 |
30 Sep 18 | 163,734 | 3,466 | 19,540 | 0 |
30 Jun 18 | 154,852 | 3,309 | 18,062 | 0 |
31 Mar 18 | 142,296 | 2,959 | 15,795 | 0 |
31 Dec 17 | 143,688 | 2,901 | 15,087 | 0 |
30 Sep 17 | 143,252 | 2,759 | 14,277 | 0 |
30 Jun 17 | 142,276 | 2,602 | 13,380 | 0 |
31 Mar 17 | 142,003 | 2,577 | 13,395 | 0 |
31 Dec 16 | 140,316 | 2,526 | 13,279 | 0 |
30 Sep 16 | 132,253 | 2,161 | 12,534 | 0 |
30 Jun 16 | 129,313 | 1,889 | 12,274 | 0 |
31 Mar 16 | 123,770 | 2,103 | 11,766 | 0 |
31 Dec 15 | 122,785 | 2,388 | 11,692 | 0 |
31 Dec 14 | 108,575 | 2,116 | 9,955 | 0 |
31 Dec 13 | 91,313 | 2,061 | 9,248 | 0 |
Kwaliteitswinsten: 3320 has high quality earnings.
Groeiende winstmarge: 3320's current net profit margins (1.5%) are higher than last year (1.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 3320's earnings have grown by 4.3% per year over the past 5 years.
Versnelling van de groei: 3320's earnings growth over the past year (11.7%) exceeds its 5-year average (4.3% per year).
Winst versus industrie: 3320 earnings growth over the past year (11.7%) exceeded the Pharmaceuticals industry 6.4%.
Rendement op eigen vermogen
Hoge ROE: 3320's Return on Equity (8.5%) is considered low.